The House Energy and Commerce Committee on Wednesday approved a comprehensive package reauthorizing the user fees that help fund the FDA, a key step in moving the must-pass legislation to a vote in the full chamber.
Committee members voted 55-0 in support of legislation (H.R. 7667) that governs the fees the drug and device industries pay to the Food and Drug Administration to make improvements to its review and approval process. The latest agreement must be reauthorized before the current user fee agreements expire Sept. 30.
“This bill has been crafted with consensus in mind from the start, ...